Valuation: Charles River Laboratories International, Inc.

Market Cap 1.41TCr 1.21TCr 1.13TCr 1.03TCr 1.94TCr 1,34800Cr 1.97TCr 13TCr 5.2TCr 68TCr 5.29TCr 5.18TCr 2,24000Cr P/E 2026 *
79x
P/E 2027 * 31.6x
Enterprise Value 1.62TCr 1.39TCr 1.3TCr 1.19TCr 2.23TCr 1,55000Cr 2.26TCr 15TCr 5.98TCr 78TCr 6.08TCr 5.95TCr 2,57600Cr EV / Sales 2026 *
4.14x
EV / Sales 2027 * 3.93x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
1 week+5.47%
Current month+26.98%
1 month+34.62%
3 months+85.91%
6 months+74.73%
Current year+47.92%
1 week 279.09
Extreme 279.09
299.22
1 month 216.99
Extreme 216.99
299.22
3 years 91.87
Extreme 91.87
299.22
5 years 91.87
Extreme 91.87
460
10 years 67.23
Extreme 67.23
460
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+5.47%+91.05%+46.88% 1.41TCr
+1.09%+5.26%+4.44%+26.03% 5.16TCr
-1.07%+2.82%+474.18%+601.24% 4.49TCr
+1.47%+9.79%+40.15%+21.21% 4.28TCr
+1.44%+7.77%+19.27%+90.94% 4.26TCr
-0.93%-4.33%+17.87%+51.96% 3.18TCr
+1.32%+7.30%+36.93%+152.36% 1.73TCr
-0.60%+1.93% - - 1.66TCr
+0.03%+3.41%+7.12%+35.49% 1.48TCr
+1.28%+5.41%+91.01%+46.93% 1.41TCr
Average +0.45%+4.43%+86.89%+119.23% 3.07TCr
Weighted average by Cap. +0.49%+4.72%+101.97%+143.29%

Financials

2026 *2027 *
Net sales 391.1Cr 335.02Cr 313.47Cr 286.94Cr 538.51Cr 37TCr 545.62Cr 3.7TCr 1.44TCr 19TCr 1.47TCr 1.44TCr 62TCr 400.08Cr 342.71Cr 320.66Cr 293.53Cr 550.87Cr 38TCr 558.15Cr 3.79TCr 1.48TCr 19TCr 1.5TCr 1.47TCr 64TCr
Net income 16Cr 14Cr 13Cr 12Cr 22Cr 1.55TCr 23Cr 153.74Cr 60Cr 780.33Cr 61Cr 60Cr 2.58TCr 43Cr 37Cr 34Cr 31Cr 59Cr 4.09TCr 60Cr 404.99Cr 157.93Cr 2.06TCr 160.59Cr 157.09Cr 6.8TCr
Net Debt 211.22Cr 180.93Cr 169.3Cr 154.97Cr 290.84Cr 20TCr 294.68Cr 2TCr 780.01Cr 10TCr 793.12Cr 775.87Cr 34TCr 163.07Cr 139.68Cr 130.7Cr 119.64Cr 224.53Cr 16TCr 227.5Cr 1.54TCr 602.18Cr 7.84TCr 612.31Cr 598.99Cr 26TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
-
Date Price Change
21/26/21 $295.33 +1.32%
20/26/20 $291.48 +0.58%
19/26/19 $289.80 +3.84%
18/26/18 $279.09 -2.63%
17/26/17 $286.63 +2.36%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
295.19USD
Average target price
281.00USD
Spread / Average Target
-4.81%

Quarterly revenue - Rate of surprise